

Table 6. Comparison of Visual Outcomes in Patients Treated with Laser + Ranibizumab versus Ranibizumab Alone with Last Observation Carried Forward

	BRVO			CRVO		
	RBZ + Laser (n=20)	RBZ alone (n=19)	p-value	RBZ + Laser (n=18)	RBZ alone (n=20)	p-value
Week 48						
Mean BCVA						
Week 24, letter score	69.9±3.1	60.8±2.9	0.04	63.1±3.3	61.7±4.4	0.92
Week 48	62.4±2.7	63.3±3.4	0.83	59.8±4.1	61.5±4.7	0.46
Change from baseline to week 48	-7.5±1.9	2.5±2.0	<0.001	-3.3±2.7	-0.2±1.9	0.36
Week 96						
Mean BCVA						
Week 24, letter score	69.9±3.1	60.8±2.9	0.04	63.1±3.3	61.7±4.4	0.92
Week 96	67.7±3.2	65.3±2.8	0.58	14.3±3.4	20.7±4.6	0.99
Change from baseline to week 96	-2.2±1.7	4.4±2.7	0.02	0.3±2.8	-1.6±2.6	0.63
Week 144						
Mean BCVA						
Week 24, letter score	69.9±3.1	60.8±2.9	0.04	63.1±3.3	61.7±4.4	0.92
Week 144	67.1±3.2	63.8±3.4	0.48	63.3±3.7	55.6±5.5	0.63
Change from baseline to week 144	-2.8±1.9	2.9±2.8	0.12	0.17±3.6	-6.1±2.9	0.18